Neurosense Therapeutics LTD reports a Return on Equity (ROE) of 713.14%.

What is NRSN's dividend yield?

Neurosense Therapeutics LTD offers a dividend yield of 0.00%.

What is NRSN's Quality Score?

Our AI rates NRSN's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy NRSN?

Our AI Timing Score for NRSN is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does NRSN belong to?

Neurosense Therapeutics LTD is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Neurosense Therapeutics LTD (NRSN) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2025-12-31)

NRSN AI Analysis Summary

Our AI summary for NRSN: Neurosense Therapeutics LTD (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 713.14%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

NRSN

Neurosense Therapeutics LTD

US:NASDAQ STOCK Healthcare >> Biotechnology News 91

USD 0.52

0.05 (11.33%) Day Change

Watchlist Portfolio Compare Chart

-0.06

D/E

713.1%

ROE

-1,082.2%

ROA

0.00%

Div Yield

NEUROSENSE THERAPEUTICS LTD
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 0.52 Price 0.05 (11.33%) Day Change	NEWS SCORE: 91

NRSN, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	91
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	0.52
PBV / Sector	-8.52 / 44,022.72
Earning Per Share	-0.44

PE / Sector	N/A / 19.17
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	0.16 M GREAT
Average 1W Daily Value	0.43 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.24
NPM Average (%) / Sector	N/A / -1,697.63
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-1,082.20 / 185,260.96
ROA Average (%) / Sector	-445.69 / 36,684.70
ROA Change Average (%) / Sector	151.17 / 422,221.66 GREAT
ROE (%) / Sector	713.14 / 243,762.23 GREAT
ROE Average (%) / Sector	168.21 / 48,758.47 GREAT
ROE Change Average (%) / Sector	-270.28 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:36
Symbol	NRSN
Name	NEUROSENSE THERAPEUTICS LTD
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	36.10 M
Par Value	N/A
Calculated From	YearEnd
Sign	N/A
Market Cap (M.USD) / Sector Average	13.29 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Building B, Herzliya, Israel, 4672562

Phone: 972 9 799 6183

Website: https://www.neurosense-tx.com

Sector: Healthcare >> Biotechnology

Description: NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.